公开(公告)号：EP1960775A2

公开(公告)日：2008-08-27

申请号：EP06849923.5

申请日：2006-12-06

申请人： University of Florida Research Foundation, Inc.

发明人： MELKER, Richard, J. ,  DENNIS, Donn, Michael ,  BJORAKER, David, G. ,  GOLD, Mark, S.

IPC分类号： G01N33/497

CPC分类号： A61M16/01 ,  A61B5/082 ,  A61B5/14532 ,  A61B5/14546 ,  A61B5/411 ,  A61B5/4821 ,  A61B5/7267 ,  A61M16/0051 ,  A61M16/026 ,  A61M16/0808 ,  A61M16/0841 ,  A61M16/1045 ,  A61M16/18 ,  A61M16/22 ,  A61M2016/0036 ,  A61M2016/1035 ,  A61M2202/0275 ,  A61M2202/0486 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3561 ,  A61M2205/3584 ,  A61M2205/52 ,  A61M2205/80 ,  A61M2230/43 ,  A61M2230/432 ,  A61M2230/435 ,  A61M2230/437 ,  G01N33/497

摘要： The present invention includes systems and methods for monitoring endogenous compound concentration in blood by detecting markers, such as odors, upon exhalation by a patient, wherein such markers are the endogenous compound itself or result from the endogenous compound. In the case of olfactory markers, the invention preferably utilizes electronic sensor technology, such as the commercial devices referred to as 'artificial' or 'electronic' noses or tongues, to non-invasively monitor endogenous compound level s in blood. The invention further includes a reporting system capable of tracking endogenous compound concentrations in blood (remote or proximate locations) and providing the necessary alerts with regard to emergent or harmful conditions in a patient.

摘要翻译： 本发明包括通过在患者呼气时检测诸如气味之类的标记物来检测血液中的内源性化合物浓度的系统和方法，其中所述标志物是内源化合物本身或由内源化合物产生。 在嗅觉标记的情况下，本发明优选利用诸如被称为“人造”或“电子”鼻子或舌头的商业装置的电子传感器技术非侵入性地监测血液中的内源性化合物水平。 本发明还包括能够跟踪血液中的内源性化合物浓度（偏远或邻近位置）并提供关于患者的紧急或有害状况的必要警报的报告系统。

公开(公告)号：EP3247271A1

公开(公告)日：2017-11-29

申请号：EP15700491.2

申请日：2015-01-19

申请人： T&W Engineering A/S

发明人： TØPHOLM, Richard ,  JENSEN, Rasmus Stig ,  CHRISTENSEN, Erik Skov ,  MADSEN, Rasmus Elsborg

IPC分类号： A61B5/157 ,  A61B5/15 ,  A61B5/145 ,  A61M5/142 ,  A61M5/172 ,  A61B5/155

CPC分类号： A61B5/4839 ,  A61B5/0476 ,  A61B5/0478 ,  A61B5/14532 ,  A61B5/150022 ,  A61B5/15087 ,  A61B5/150877 ,  A61B5/155 ,  A61B5/157 ,  A61B5/6814 ,  A61B5/6817 ,  A61B5/7405 ,  A61B5/746 ,  A61M5/142 ,  A61M5/14244 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2202/0486 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/581 ,  A61M2230/10 ,  A61M2230/201

摘要： A system for adjusting blood glucose level including an insulin delivery device configured to release insulin into the body of a person, and an EEG monitor having an EEG sensing part including EEG electrodes. The EEG monitor can be arranged in the ear region of the person with the EEG sensing part arranged subcutaneously at the scalp or arranged in the ear canal. The EEG monitor includes an EEG signal processor arranged at the ear and adapted for identifying onset of hypoglycemia. The system further includes a wireless link between the EEG monitor and the insulin delivery device. The EEG monitor is configured to submit a warning signal to the insulin delivery device if an upcoming onset of hypoglycemia is identified. The warning message will cause the insulin delivery device to restrict insulin delivery for a predetermined time, and a warning is provided to the person or to a caregiver.

公开(公告)号：EP2735320B1

公开(公告)日：2016-10-26

申请号：EP13194082.7

申请日：2013-11-22

申请人： Becton Dickinson and Company

发明人： Petisce, James R. ,  Metters, Andrew

IPC分类号： A61M1/14 ,  A61M1/36 ,  A61M1/34

CPC分类号： A61M1/14 ,  A61M1/342 ,  A61M1/3609 ,  A61M1/3621 ,  A61M1/3679 ,  A61M2202/0486 ,  A61M2230/201

公开(公告)号：EP2488231B1

公开(公告)日：2013-12-04

申请号：EP10772969.1

申请日：2010-10-11

申请人： ResuSciTec GmbH

发明人： BEYERSDORF, Friedhelm

IPC分类号： A61M5/168 ,  A61M5/172 ,  A61M1/36 ,  A61M5/142 ,  A61M5/44

CPC分类号： A61M5/1723 ,  A61B5/14539 ,  A61B5/14546 ,  A61B5/14557 ,  A61M1/3639 ,  A61M1/3666 ,  A61M1/3687 ,  A61M1/369 ,  A61M5/16827 ,  A61M5/44 ,  A61M2005/14272 ,  A61M2202/0468 ,  A61M2202/0486 ,  A61M2202/07 ,  A61M2205/52 ,  A61M2210/125 ,  A61M2230/20 ,  A61M2230/201 ,  A61M2230/202 ,  A61M2230/205 ,  A61M2230/208 ,  A61M2230/30 ,  A61M2230/50

摘要： The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising blood withdrawal means (BE) that can be applied to the individual (P), an analysis unit (BA) directly or indirectly connected to the blood withdrawal means for detecting and providing, in the form of a blood analysis result (BAE), at least one characteristic of the blood, directly or indirectly connected to a return means (BR) that can be applied to the individual (P) and is designed to deliver a substance to the individual via the return means (BR).

公开(公告)号：EP3164170A1

公开(公告)日：2017-05-10

申请号：EP15815601.8

申请日：2015-07-01

申请人： Bigfoot Biomedical, Inc.

发明人： ESTES, Mark C.

IPC分类号： A61M5/00 ,  A61M5/14 ,  A61M5/142

CPC分类号： A61M5/1723 ,  A61K38/26 ,  A61M5/003 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/24 ,  A61M2202/0486 ,  A61M2205/3561 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201 ,  G06F19/00 ,  G06F19/3468 ,  G16H20/17

摘要： Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

摘要翻译： 基于一个或多个特定参数（例如，用户的最近血糖特征，用户的胰高血糖素敏感性值和其他参数），胰高血糖素施用系统的一些实施方案可以提供建议的胰高血糖素剂量。 在一些情况下，胰高血糖素施用系统可以接收指示用户的血糖水平的信息并且建议胰高血糖素剂量至少部分取决于用户先前存储的胰高血糖素敏感性。

公开(公告)号：EP3096793A1

公开(公告)日：2016-11-30

申请号：EP14786572.9

申请日：2014-10-07

申请人： Boston Scientific Scimed, Inc. ,  Smith, Paul ,  Torres, Felipe ,  Raybin, Samuel ,  Timm, Mary Jo

发明人： SMITH, Paul ,  TORRES, Felipe ,  RAYBIN, Samuel ,  TIMM, Mary Jo

IPC分类号： A61K47/36 ,  A61K47/38 ,  A61L31/04 ,  A61L31/14 ,  C08L5/00

CPC分类号： A61K9/0019 ,  A61B1/018 ,  A61B17/22 ,  A61B17/3478 ,  A61B2017/00269 ,  A61B2017/0034 ,  A61B2017/22082 ,  A61K9/0031 ,  A61K9/0053 ,  A61K47/02 ,  A61K47/36 ,  A61K47/38 ,  A61M5/178 ,  A61M25/0084 ,  A61M2202/0007 ,  A61M2202/0486 ,  C08L1/286 ,  C08L5/00 ,  C08L5/08 ,  D01D5/253 ,  D01D5/30 ,  D01F8/04 ,  Y10T428/2929

摘要： In one aspect, the invention provides injectable compositions that comprise a suitable hydrophilic polymer (e.g., a suitable polysaccharide) and water, as well as other optional components. In various embodiments, the composition may be provided in a suitable container, for example, in a pre-loaded syringe. In another aspect, methods of performing medical procedures in a tract of a body are provided. In yet another aspect, the invention provides systems for performing medical procedures in a tract of a body.

摘要翻译： 在一个方面，本发明提供了包含合适的亲水性聚合物（例如合适的多糖）和水以及其它任选组分的可注射组合物。 在各种实施方案中，组合物可以设置在合适的容器中，例如在预加载的注射器中。 在另一方面，提供了在身体的道中进行医疗程序的方法。 在另一方面，本发明提供了用于在身体的道中执行医疗程序的系统。

公开(公告)号：EP2488231A1

公开(公告)日：2012-08-22

申请号：EP10772969.1

申请日：2010-10-11

申请人： Universitätsklinikum Freiburg

发明人： BEYERSDORF, Friedhelm

IPC分类号： A61M5/168 ,  A61M5/172 ,  A61M1/36 ,  A61M5/142 ,  A61M5/44

CPC分类号： A61M5/1723 ,  A61B5/14539 ,  A61B5/14546 ,  A61B5/14557 ,  A61M1/3639 ,  A61M1/3666 ,  A61M1/3687 ,  A61M1/369 ,  A61M5/16827 ,  A61M5/44 ,  A61M2005/14272 ,  A61M2202/0468 ,  A61M2202/0486 ,  A61M2202/07 ,  A61M2205/52 ,  A61M2210/125 ,  A61M2230/20 ,  A61M2230/201 ,  A61M2230/202 ,  A61M2230/205 ,  A61M2230/208 ,  A61M2230/30 ,  A61M2230/50

摘要： The invention relates to a device for treating an individual suffering from cardiac or circulatory arrest or from a stroke, comprising blood withdrawal means (BE) that can be applied to the individual (P) for taking at least some of the individual's blood, an analysis unit (BA) directly or indirectly connected to the blood withdrawal means for detecting and providing in the form of a blood analysis result (BAE) at least one characteristic of the blood, an operative unit (KE) directly or indirectly connected to a return means (BR) that can be applied to the individual (P) and is designed to deliver a substance to the individual via the return means (BR). The invention is characterised in that the operative unit (KE) comprises at least one reservoir unit (R) storing supplies of at least two substances (S
1 , S
2 ,...), a dosage unit (D) combined with the reservoir unit (R) is provided, which dosage unit, at least taking into consideration a blood analysis result (BAE) determined by means of the analysis unit (BA), selects from the at least two substances (S
1 , S
2 ,...) at least one substance or produces a mixture of at least two of the substances (S
1 , S
2 ,...), and the at least one selected substance or the mixture can be introduced into the individual directly or indirectly via the return means (BR).

摘要翻译： 本发明涉及一种设备，用于处理从心脏或停循环或从一个行程个体痛苦，包括采血器（BE）也被施加到个体（P），以分析单元（BA），所有这些直接或间接地 连接到所述血液抽取装置，用于检测血液的分析结果（BAE）提供血液的至少一个特性，直接或间接地连接到血液返回装置（BR）没有被施加到单独的（P）和旨在提供 的物质经由所述返回装置（BR）的个体。

公开(公告)号：EP3164170A4

公开(公告)日：2018-03-21

申请号：EP15815601

申请日：2015-07-01

申请人： BIGFOOT BIOMEDICAL INC

发明人： ESTES MARK C

IPC分类号： G16H20/17 ,  A61M5/00 ,  A61M5/14 ,  A61M5/142

CPC分类号： A61M5/1723 ,  A61K38/26 ,  A61M5/003 ,  A61M5/14244 ,  A61M5/14248 ,  A61M5/24 ,  A61M2202/0486 ,  A61M2205/3561 ,  A61M2205/3584 ,  A61M2205/3592 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/8206 ,  A61M2230/201 ,  G06F19/3468 ,  G16H20/17

摘要： Some embodiments a glucagon administration system can provide a suggested glucagon dosage based on one or more particular parameters (e.g., the user's recent blood glucose characteristics, a glucagon sensitivity value of the user, and other parameters). In some circumstances, the glucagon administration system can receive information indicative of the user's blood glucose level and suggest a glucagon dosage that is at least partially dependent upon a previously stored glucagon sensitivity for the user.

公开(公告)号：EP2178596A4

公开(公告)日：2014-08-13

申请号：EP08789092

申请日：2008-08-08

申请人： FORD HENRY HEALTH SYSTEM

发明人： SZAMOSFALVI BALAZS ,  FRINAK STANLEY ,  YEE JERRY

IPC分类号： A61M37/00 ,  A61M1/34 ,  A61M1/36

CPC分类号： A61M1/3672 ,  A61M1/3406 ,  A61M1/3413 ,  A61M1/3434 ,  A61M1/3437 ,  A61M1/3441 ,  A61M1/3455 ,  A61M1/3458 ,  A61M1/3609 ,  A61M1/3653 ,  A61M1/3656 ,  A61M1/3658 ,  A61M1/3675 ,  A61M2202/0486 ,  A61M2205/3306

公开(公告)号：EP2735320A1

公开(公告)日：2014-05-28

申请号：EP13194082.7

申请日：2013-11-22

申请人： Becton, Dickinson and Company

发明人： Petisce, James R. ,  Metters, Andrew

IPC分类号： A61M1/14 ,  A61M1/36 ,  A61M1/34

CPC分类号： A61M1/14 ,  A61M1/342 ,  A61M1/3609 ,  A61M1/3621 ,  A61M1/3679 ,  A61M2202/0486 ,  A61M2230/201

摘要： A process and apparatus are provided for managing and adjusting glucose levels in the blood of a patient during dialysis. The apparatus is a dialysis apparatus to treat patients with renal disease which includes a glucose scavenger to remove excess glucose from the blood before returning the blood to the patient and/or a device to increase blood glucose levels in the blood when the glucose level is below a threshold level. The glucose scavenger can include a glucose binding protein, boronic acid derivative, boronic ester derivative or mixture thereof bonded to the surface of a support such as a fiber bundle in a cartridge or the inner surface of tubing used in the apparatus.

摘要翻译： 提供了一种用于在透析期间管理和调节患者血液中的葡萄糖水平的方法和装置。 该装置是一种透析装置，用于治疗患有肾脏疾病的患者，其包括葡萄糖清除剂，以在血液返回到患者之前除去血液中的多余葡萄糖，和/或当葡萄糖水平低于血液时增加血液中的血糖水平的装置 阈值水平。 葡萄糖清除剂可以包括葡萄糖结合蛋白，硼酸衍生物，硼酸酯衍生物或其结合到载体表面的混合物，例如药筒中的纤维束或装置中使用的管的内表面。